EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance

Hideto Kameda iD, Sadatomo Tasaka, Toshiya Takahashi, Katsuhisa Suzuki, Naoki Soeda, Yoshiya Tanaka

Modern Rheumatology · 2024

DOI: 10.1093/mr/road055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Hideto Kameda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

An interim analysis of post-marketing surveillance data to assess the safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatment.

Methods

The interim analysis included patients who initiated sarilumab therapy between June 2018 and January 2021. The primary objective of this surveillance was safety.

Results

In total, 1036 patients were enrolled and registered by 12 January 2021 (interim cut-off date). Of these, 678 were included in the safety analysis [75.4% female; mean age (± standard deviation) 65.8 ± 13.0 years]. Adverse drug reactions, defined as adverse events classified as possibly or probably related to sarilumab, were reported in 170 patients (incidence: 25.1%), with white blood cell count decreased (4.4%) and neutrophil count decreased (1.6%) most frequently reported. Serious haematologic disorders (3.4%) and serious infections (including tuberculosis) (2.5%) were the most frequently reported priority surveillance items. No malignant tumour was reported. An absolute neutrophil count (ANC) below the minimum standard value did not increase the incidence of serious infections.

Conclusions

Sarilumab was well tolerated, and no new safety signals were noted in this analysis. There was no difference in the frequency of serious infections between patients with an ANC below or above normal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedAgedMaleJapanTreatment OutcomeProduct Surveillance, Postmarketing

Stichwörter der Autor:innen

Interim analysispost-marketing surveillancerheumatoid arthritissafetysarilumab

Substanzen

Antirheumatic AgentssarilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
  • Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Specialty Care Medical, Sanofi K.K., Tokyo, Japan.
  • Medical Affairs, Sanofi K.K., Tokyo, Japan.
  • Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.

ORCID-Profile: Hideto Kameda

Zitieren

APA

Kameda, H., Tasaka, S., Takahashi, T., Suzuki, K., Soeda, N., & Tanaka, Y. (2024). Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance. Modern Rheumatology. https://doi.org/10.1093/mr/road055

Vancouver

Kameda H, Tasaka S, Takahashi T, Suzuki K, Soeda N, Tanaka Y. Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance. Modern Rheumatology. 2024. doi:10.1093/mr/road055

BibTeX
@article{Kameda2024,
  author = {Kameda, Hideto and Tasaka, Sadatomo and Takahashi, Toshiya and Suzuki, Katsuhisa and Soeda, Naoki and Tanaka, Yoshiya},
  title = {Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road055}
}
Kostenlos starten →